PMID- 19399518
OWN - NLM
STAT- MEDLINE
DCOM- 20090910
LR  - 20220310
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 135
IP  - 10
DP  - 2009 Oct
TI  - Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 
      receptor blockers on survival in patients with advanced non-small-cell lung 
      cancer undergoing first-line platinum-based chemotherapy.
PG  - 1429-35
LID - 10.1007/s00432-009-0587-3 [doi]
AB  - PURPOSE: The renin-angiotensin system plays a crucial role in maintaining 
      vascular homeostasis. Stimulation of angiotensin II type 1 receptors (AT1R) acts 
      proangiogenically by increasing levels of vascular endothelial growth factor 
      (VEGF). Consequently, cell culture experiments and animal studies have shown 
      antiproliferative effects of AT1R blockers (ARB) and angiotensin I converting 
      enzyme inhibitors (ACEI) in several malignancies. Until now, very limited 
      clinical data for this antiangiogenic effect exists for combinations with 
      antineoplastic chemotherapy. METHODS: A total of 287 patients with advanced 
      non-small-cell lung cancer undergoing first-line platinum-based chemotherapy were 
      retrospectively analysed regarding long-term medication with ACEI and ARB as well 
      as histological type, stage, performance status, gender, age, dose-intensity of 
      chemotherapy and survival. RESULTS: Patients receiving either ACEI or ARB had a 
      3.1 months longer median survival than non-recipients (11.7 vs. 8.6 months, HR 
      0.56, P = 0.03). This survival advantage could not be attributed to other 
      established risk-factors or dose intensity of chemotherapy. CONCLUSIONS: Addition 
      of ACEI or ARB to platinum-based first-line chemotherapy may contribute to 
      prolonged survival in patients with advanced lung cancer.
FAU - Wilop, Stefan
AU  - Wilop S
AD  - Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Pauwelsstrasse 
      30, 52074 Aachen, Germany. swilop@ukaachen.de
FAU - von Hobe, Sabine
AU  - von Hobe S
FAU - Crysandt, Martina
AU  - Crysandt M
FAU - Esser, Albert
AU  - Esser A
FAU - Osieka, Rainhardt
AU  - Osieka R
FAU - Jost, Edgar
AU  - Jost E
LA  - eng
PT  - Journal Article
DEP - 20090428
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 49DFR088MY (Platinum)
SB  - IM
MH  - Adenocarcinoma/drug therapy/mortality/secondary
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin II Type 1 Receptor Blockers/*therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Carcinoma, Adenosquamous/drug therapy/mortality/secondary
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*mortality/pathology
MH  - Carcinoma, Squamous Cell/drug therapy/mortality/secondary
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/*mortality/secondary
MH  - Male
MH  - Middle Aged
MH  - Platinum/therapeutic use
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2009/04/29 09:00
MHDA- 2009/09/11 06:00
CRDT- 2009/04/29 09:00
PHST- 2009/02/13 00:00 [received]
PHST- 2009/04/07 00:00 [accepted]
PHST- 2009/04/29 09:00 [entrez]
PHST- 2009/04/29 09:00 [pubmed]
PHST- 2009/09/11 06:00 [medline]
AID - 10.1007/s00432-009-0587-3 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2009 Oct;135(10):1429-35. doi: 
      10.1007/s00432-009-0587-3. Epub 2009 Apr 28.